Shortly after treatment, the patient developed cranial nerve palsies (III, VII, VIII), suspected to represent either an immune-related adverse event or Ramsay Hunt syndrome; his symptoms improved with prednisolone and valaciclovir, allowing Dur/Tre to be resumed. To our knowledge, this is the first report of primary hepatic undifferentiated carcinoma with high PD-L1 expression demonstrating a sustained response to Dur/Tre. This case suggests that PD-L1 expression may serve as a potential biomarker for predicting ICI responsiveness in this rare and aggressive tumor.

14 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1)

PD-L1 expression • PD-L1 overexpression

Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • valacyclovir

2ms

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (clinicaltrials.gov)

P1/2, N=62, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

2 months ago

Trial completion date • Trial primary completion date

ProstAtak (aglatimagene besadenovec) • valacyclovir

2ms

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (clinicaltrials.gov)

P1, N=11, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

valacyclovir

3ms

P1, N=11, Not yet recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Jan 2031 --> Jun 2031 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2031 --> Jun 2031

3 months ago

Trial completion date • Trial initiation date • Trial primary completion date

valacyclovir

3ms

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (clinicaltrials.gov)

P2, N=45, Recruiting, Candel Therapeutics, Inc. | N=30 --> 45

3 months ago

Enrollment change

ProstAtak (aglatimagene besadenovec) • valacyclovir

4ms

A Randomized Controlled Clinical Study on Transfer Factor Oral Solution in the Treatment of Herpes Zoster (ChiCTR2600117507)

P4, N=90, Recruiting, Dermatology Hospital, Southern Medical University; Dermatology Hospital, Southern Medical University